Trump announces trade deal with EU following months of negotiations
Charles River Laboratories International Inc. (CRL) stock has reached a 52-week low, touching down at $151.51. This significant downturn reflects a challenging year for the company, with the stock experiencing a 1-year decline of 31.39%. According to InvestingPro data, the company maintains a "GOOD" overall financial health score of 2.86, despite recent market pressures. Investors are closely monitoring the company’s performance as it navigates through market pressures that have pushed the stock to this low point. The current price level presents a critical juncture for Charles River Labs (NYSE:CRL), with analysts setting price targets ranging from $152 to $260, suggesting potential upside. InvestingPro analysis indicates the stock is currently undervalued, with 5 analysts recently revising their earnings expectations downward for the upcoming period. Discover 7 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Charles River Laboratories’ credit outlook has been revised to stable from positive by S&P Global due to weak 2025 guidance. The company anticipates a decline in revenue and pressure on operating margins. William Blair analysts have downgraded the company’s stock from Outperform to Market Perform, citing concerns about the company’s near-term prospects. Similarly, TD Cowen analysts have reduced their price target for Charles River Laboratories, citing anticipated revenue pressures. UBS analysts have also adjusted their outlook, downgrading the company’s stock rating from Buy to Neutral and reducing the price target.
Charles River Laboratories is expected to face challenges due to proposed regulatory changes affecting the industry, including a potential global ban on non-human primates from Cambodia, which are commonly used in research and development activities. This could create an incremental headwind to the company’s 2025 earnings per share. The company is also dealing with the impact of the loss of exclusivity by large pharmaceutical companies, which are now expected to focus more on products closer to approval.
These are recent developments that could affect the company’s financial performance in the coming years. While the company is implementing cost-saving initiatives expected to yield $200 million in annualized savings by 2026, analysts from different firms have expressed a cautious outlook for the company’s performance in the face of these various challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.